Results 141 to 150 of about 19,412 (203)

Osimertinib <i>vs.</i> erlotinib combined with an angiogenesis inhibitor in <i>EGFR</i>-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study. [PDF]

Transl Lung Cancer Res
Hata T, Yamada T, Mikami K, Yokoyama T, Oba T, Goto Y, Furuya N, Futamura S, Taniguchi H, Okimoto T, Hirai S, Uda S, Okada A, Watanabe R, Ishizaki N, Kawachi H, Kijima T, Takayama K.   +17 more
europepmc   +1 more source

Exceptional Response of HER2-Positive Breast Cancer to Osimertinib: A Case Report. [PDF]

Thorac Cancer
Yasui H, Hatasa M, Ohara K, Sano K, Mori Y, Shibata T, Fukui Y, Odate M, Arai Y, Fujii M, Makino Y.   +10 more
europepmc   +1 more source

Longitudinal In Vivo Imaging at Single-Lesion Resolution Identifies Allele-Associated Response and Resistance Dynamics in EGFR-Mutant Lung Cancer. [PDF]

Int J Mol Sci
Cabrera San Millan E, Panetta D, Armanetti P, Quaglierini M, Zega A, Mercatelli R, Bramanti E, Menichetti L, Maroni G, Levantini E.   +9 more
europepmc   +1 more source

Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. [PDF]

Signal Transduct Target Ther
Tan P, Liu Z, Hu X, Zhang Y, Chen H, Lan B, Ma T, Ding S.   +7 more
europepmc   +1 more source

Acquired <i>EML4-ALK</i> fusion and <i>BRAF</i> V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report. [PDF]

Front Oncol
Zhang R, Li J.
europepmc   +1 more source

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation? [PDF]

Cancer Drug Resist
Dempke WCM, Fenchel K, Sullivan L, Reck M.   +3 more
europepmc   +1 more source

Case Report: Fatal osimertinib-related interstitial lung disease during adjuvant therapy after left pneumonectomy in a patient with lung adenocarcinoma undergoing maintenance hemodialysis. [PDF]

Front Oncol
Kaki T, Harutani Y, Hirai Y, Iguchi H, Hirai I, Nishikawa M, Kitahara D, Tsuchihashi Y, Kanai K.   +8 more
europepmc   +1 more source

Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source

Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review. [PDF]

Respirol Case Rep
Nguyen TH, Nguyen HG, Le TH.
europepmc   +1 more source

Investigating the mechanism of Fuzheng Sanjie Formula in regulating osimertinib resistance in NSCLC via the CAFs-TIMP3-MMP9 axis: a study integrating network pharmacology, data mining. [PDF]

Front Oncol
Wang Y, Peng Q, Zhang Y, Wang H, Zhu J, Zhou J.   +5 more
europepmc   +1 more source